Synthetic TLR4 agonist as a potential immunotherapy for melioidosis

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Open Journal of Immunology

ISSN Print: 2162-450X
ISSN Online: 2162-4526
www.scirp.org/journal/oji
E-mail: oji@scirp.org

Google-based Impact Factor: 0.91
Citations h5-index & Ranking*

Journals Menu

"Synthetic TLR4 agonist as a potential immunotherapy for melioidosis"
written by Zi Yan Tan, Alvin K. L. Khah, Siew Hoon Sim, Vidhya Novem, Yichun Liu, Gek-Yen Gladys Tan,
published by Open Journal of Immunology, Vol.3 No.1, 2013

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases
	2020

[2]	Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer
	International Journal of Biological Macromolecules, 2018

[3]	Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches
	The Philosophical Magazine A Journal of Theoretical Experimental and Applied Physics, 2016

[1]	Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases Immunotherapy, 2020 DOI:10.2217/imt-2019-0096

[2]	Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer International Journal of Biological Macromolecules, 2019 DOI:10.1016/j.ijbiomac.2018.10.142

[3]	Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches Expert Review of Vaccines, 2016 DOI:10.1586/14760584.2016.1170598

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Open Journal of Immunology

Open Journal of Immunology

Journals Menu

Home

About SCIRP

Service

Policies